Get to know our clinical trials
Study to evaluate the efficacy and safety of treatment combinations based on multiple immunotherapies in patients with metastatic non-small cell lung carcinoma
THE PURPOSE IS TO EVALUATE THE DRUG ATEZOLIZUMAB (ITA) IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN (CHEMOTHERAPY) TO FIND OUT WHAT EFFECTS THIS TREATMENT HAS, WHETHER GOOD OR BAD, ON YOU AND YOUR LUNG CANCER.
- UNBLINDED, MULTICENTER, RANDOMIZED, PHASE IB/II UMBRELLA STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS BASED ON MULTIPLE IMMUNOTHERAPIES IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CARCINOMA (PULMONARY MORPHEUS)
- Code EudraCT: 2017-001267-21
- Protocol number: BO39610
- Promoter: Roche Farma, S.A.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies